Navigation Links
A double block of blood vessels to starve cancerous tumors
Date:12/9/2010

A novel strategy of blocking the growth of blood vessels with antibodies should result in improved treatment of cancerous tumors.

The growth of new blood vessels from pre-existing vasculature is called angiogenesis. In adults, angiogenesis occurs only during wound healing and menstrual cycling, but is abundant and harmful in cancerous tumors and the old-age eye disease frequently leading to blindness called age-related macular degeneration (AMD). Without the formation of new blood vessels, tumors cannot grow beyond a small size due to lack of oxygen and nutrients. Inhibition of angiogenesis is used in the treatment of cancer and AMD, but not all cancer patients respond, while others become refractory to therapy.

Academy professor Kari Alitalo and co-workers at the University of Helsinki, Finland, have previously shown that antibodies directed towards vascular endothelial growth factor receptor (VEGFR)-3, found on the surface of endothelial cells lining vessels, can inhibit lymphatic metastasis by 50-70% in preclinical tumor models. Furthermore, antibodies that inhibited the growth factor VEGF-C from binding to the VEGFR-3 suppressed angiogenesis. However, the trouble with this type of inhibitors is that they work poorly in high growth factor concentrations, when the growth factor easily outcompetes the inhibitor. Also the delivery of drugs into tumors is hampered by erratic blood flow and high tumor pressure, which may prevent sufficient amounts of the inhibitor from reaching its target within the tumor.

The novel type of VEGFR-3 blocking antibody has an unprecedented mechanism of action, which was effective even at very high concentrations of the VEGF-C growth factor. Importantly, the authors showed that combined use of antibodies blocking growth factor binding VEGFR-3 dimerization provided not only an additive, but rather a synergistic inhibition.

"The new dimerization inhibitor unveils a biologically meaningful rationale for suppressing angiogenesis in tumors that could outperform traditional competitive inhibitors of angiogenesis in tumor therapy. These findings should translate into improved anti-angiogenic and anti-lymphangiogenic tumor therapies", says Professor Alitalo.


'/>"/>

Contact: Kari Alitalo
kari.alitalo@helsinki.fi
358-505-003-572
University of Helsinki
Source:Eurekalert  

Related medicine news :

1. Major depression more than doubles risk of dementia among adults with diabetes
2. Obesity, Drinking a Double Threat to the Liver
3. De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V
4. Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer
5. Obesity and weight gain near time of prostate cancer surgery doubles risk of recurrence
6. Look Out KFC Double Down, IHOP Pancake Stacker & BK Mimosa - Freshii Launches Zero Calorie Menu with Elemental Sides
7. Radiation Risks Nearly Double for Younger CT Scan Patients
8. Medical costs of cancer have nearly doubled over the past 2 decades
9. U.S. Cancer Costs Double in Two Decades
10. Female-to-Male HIV Transmission Risk Doubles During Pregnancy
11. Pregnancy doubles HIV risk in men; first trial of a microbicide in pregnant women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A double block of blood vessels to starve cancerous tumors
(Date:5/24/2017)... ... May 24, 2017 , ... Adelberg-Montalvan Pediatric ... options for its patients on Long Island, New York. , Holistic dentistry ... and is one of the biggest trends in dentistry today. , Dentist ...
(Date:5/24/2017)... ... 24, 2017 , ... Fiberstar, Inc., http://www.FiberstarIngredients.com a ... beverage industry offers Citri-Fi®, a natural citrus fiber, to improve beverage ingredient declarations. ... a result, labels need to deliver simple, transparent and clear messaging. Listed food ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International ... company, announced today that its iClinic V12.2 solution has achieved approval from National ... recently introduced PCMH 2017 standards which emphasize team-based care with a significant focus ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... pharmaceutical and medical device sectors, today announced the winners of its 3rd Annual ... represent the most influential people in the healthcare industry today. , Out of ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... a 2017 Best in KLAS category winner, has named Daniel P. Bullington as ... and enhance its technology platform and product offerings,” says Justin Neece, president. “Daniel ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
(Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. ... Communications, Inc. ("WRB"), a health care service center ... WRB specializes in relationship management programs for ... WRB will join ... commercialization support services for manufacturers, biotech firms, and other ...
Breaking Medicine Technology: